PD-1/PD-L1信号通路在子宫内膜癌中的研究进展

子宫内膜癌作为女性生殖系统三大恶性肿瘤之一，早期治疗方法包括手术、放疗、化疗和内分泌治疗。晚期患者易发生转移或复发，预后较差。近年来靶向免疫检查点治疗成为肿瘤治疗的新热点，其中程序性死亡受体1/程序性死亡配体1(PD-1/PD-L1)在临床实验中显示出了较好的疗效和耐受性，本文将对PD-1/PD-L1信号通路相关的生物学基础，作用机制，其在子宫内膜癌及肿瘤微环境中表达及临床应用进行综述。

Progress in the study of PD-1/PD-L1 signaling pathway in endometrial cancer

Endometrial cancer is one of the three major malignant tumors of female reproductive system.The early treatment includes surgery,radiotherapy,chemotherapy and endocrine therapy.Patients with advanced stage are prone to metastasis or recurrence and have poor prognosis.In recent years,targeted immune checkpoint therapy has become a new hotspot of tumor therapy,in which programmed death receptor 1/programmed death ligand 1(PD-1/PD-L1)has shown good efficacy and tolerance in clinical trials.In this paper,the biological basis,mechanism,expression and clinical application of PD-1/PD-L1 signaling pathway in endometrial cancer and tumor microenvironment are reviewed.